All In Biotech

Drug Trial Radar · NCT01471340

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in Adolescents and Adults With Persistent Asthma (Protocol No. P06241 Also Known as P202)

Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 11,744 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

11,744

Actual

Start

Jan 9, 2012

Primary completion

Nov 30, 2016

Study completion Nov 30, 2016

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Nov 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the safety of DULERA. DULERA is a pressurized metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and formoterol in a single inhaler. Mometasone is an inhaled corticosteroid (ICS), which reduces the inflammation in the airways. Formoterol is a long-acting beta 2 agonist (LABA), which helps to relax the muscles of the airways in the lungs, making it easier to breathe. In combination, mometasone and formoterol are used for the treatment of asthma. This study will evaluate whether participants taking a LABA in combination with an ICS in a single inhaler have a different risk of having serious asthma events (hospitalization, intubation and death) compared to participants taking an ICS alone. The primary safety hypothesis is that the time-to-first serious asthma outcome (SAO) with mometasone furoate/formoterol (MF/F) MDI twice daily (BID) is non-inferior to that with mometasone furoate (MF) MDI BID in adolescents and adults with persistent asthma. If non-inferiority is achieved, the key secondary safety hypothesis of superiority of MF/F over MF will be assessed.

Conditions

  • Asthma

Interventions

  • Mometasone Furoate/Formoterol MDI 100/5 mcgDrug

    two inhalations BID

  • Mometasone Furoate/Formoterol MDI 200/5 mcgDrug

    two inhalations BID

  • Mometasone Furoate MDI 100 mcgDrug

    two inhalations BID

  • Mometasone Furoate MDI 200 mcgDrug

    two inhalations BID

  • Albuterol 90 mcg /salbutamol 100 mcg HFA MDIDrug

    use as needed for asthma symptoms

  • Prednisone/prednisoloneDrug

    Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to-First Serious Asthma Outcomes (SAO): Number of First SAO in the MF/F vs MF ArmsTime frame: 26 weeks, or 7 days after the last treatment dose, whichever occurred later

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.